If you’ve been following the buzz around weight loss medications, you may have noticed two names that keep appearing side by side: Mounjaro and Zepbound. They sound different, they’re marketed differently, and they even have different price tags — yet they contain the exact same active ingredient. So what’s really going on?

Here’s the full story behind tirzepatide’s dual identity, and what it means for you.

The Same Molecule, Two Different Labels

Both Mounjaro and Zepbound are brand names for tirzepatide, a injectable medication developed by Eli Lilly. The key difference isn’t in the drug itself — it’s in the FDA-approved indication, meaning the official medical purpose each version is authorized to treat.

• Mounjaro was approved by the FDA in May 2022 for the treatment of type 2 diabetes. It helps lower blood sugar levels by mimicking two gut hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).
• Zepbound was approved by the FDA in November 2023 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition, such as high blood pressure or sleep apnea.

Same molecule. Same doses. Different box, different approval, and critically — different insurance coverage.

How Tirzepatide Works

What makes tirzepatide stand out from earlier GLP-1 drugs like semaglutide (Ozempic, Wegovy) is its dual-action mechanism. By activating both GLP-1 and GIP receptors, tirzepatide:

• Slows gastric emptying, keeping you feeling full longer
• Reduces appetite by acting on hunger signals in the brain
• Improves insulin sensitivity, helping the body manage blood sugar more effectively
• Promotes fat burning through metabolic pathways influenced by GIP

In clinical trials (the SURMOUNT trials for weight loss), participants taking the highest dose of tirzepatide lost an average of 22.5% of their body weight over 72 weeks — results that were unprecedented in the history of anti-obesity medication.

Dosing: Is There Any Difference?

The dosing schedule for Mounjaro and Zepbound is virtually identical. Both are administered as a once-weekly subcutaneous injection (under the skin) and are available in the same dose strengths:

• 2.5 mg (starting dose)
• 5 mg
• 7.5 mg
• 10 mg
• 12.5 mg
• 15 mg (maximum dose)

Patients typically start at 2.5 mg and titrate up every four weeks as tolerated, with the goal of reaching the most effective dose while minimizing side effects like nausea, vomiting, and diarrhea.

Who Qualifies for Each?

This is where the distinction becomes clinically meaningful.

Mounjaro is prescribed to adults with type 2 diabetes who need better blood sugar control. It’s often used alongside diet and exercise, and sometimes in combination with other diabetes medications.

Zepbound is prescribed to adults who:

• Have a BMI of 30 or higher (obesity), or
• Have a BMI of 27 or higher (overweight) plus a weight-related health condition like hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea

Importantly, a person with type 2 diabetes who also needs to lose weight might be prescribed either version, depending on what their insurance covers.

The Insurance Question — and Why It Matters

Here’s where things get frustrating for patients.

Mounjaro is more likely to be covered by insurance for people with type 2 diabetes, because diabetes treatment is broadly recognized by payers as medically necessary.

Zepbound, on the other hand, faces a steeper climb. Many insurance plans — including standard Medicare — still do not cover anti-obesity medications, meaning patients may pay out of pocket. Without insurance, Zepbound’s list price hovers around $1,000–$1,100 per month.

Some patients have discovered that Mounjaro’s manufacturer savings card can bring costs as low as $25–$550 per month for eligible commercially insured patients. Zepbound has its own savings program as well. However, these programs exclude Medicare and Medicaid recipients.

Can You Switch Between the Two?

If you’re currently on Mounjaro for diabetes and your doctor believes Zepbound’s weight management protocol is a better fit — or vice versa — the transition is straightforward from a pharmacological standpoint, since the drug is identical. The main considerations are:

• Insurance authorization: Your insurer may require a new prior authorization for the different indication
• Formulary placement: Mounjaro and Zepbound may be placed differently on your plan’s drug formulary
• Documentation: Your physician may need to submit different supporting clinical notes depending on the indication

The Bottom Line

Mounjaro and Zepbound are, at their core, the same medication doing the same things in your body. The distinction exists primarily in the regulatory and insurance landscape — not in the pharmacology.

If you’re living with type 2 diabetes, Mounjaro may be your path to access. If you’re seeking treatment for obesity without a diabetes diagnosis, Zepbound is the FDA-approved route. And if you have both conditions? Talk to your doctor about which label is most likely to get covered — because the drug in the pen is the same either way.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.